Cargando…
Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
INTRODUCTION: Bone metastasis is the most common complication of advanced breast cancer. The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid. Clinical trials have shown that zoledronic acid also reduces breast cancer recurrence in bone; potentially by...
Autores principales: | Haider, Marie-Therese, Holen, Ingunn, Dear, T. Neil, Hunter, Keith, Brown, Hannah K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127787/ https://www.ncbi.nlm.nih.gov/pubmed/24971713 http://dx.doi.org/10.1016/j.bone.2014.06.023 |
Ejemplares similares
-
Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo
por: Haider, Marie-Therese, et al.
Publicado: (2015) -
The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche in vivo
por: Allocca, Gloria, et al.
Publicado: (2019) -
The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells
por: Brown, Hannah K, et al.
Publicado: (2011) -
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
por: Ubellacker, Jessalyn M., et al.
Publicado: (2017) -
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021)